Clinical Trials Logo

Triple Negative Breast Cancer clinical trials

View clinical trials related to Triple Negative Breast Cancer.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06309459 Completed - Clinical trials for Triple Negative Breast Cancer

Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma

Start date: August 1, 2018
Phase:
Study type: Observational

Triple-negative breast carcinoma is characterized by the absence of estrogen receptors, progesterone receptors, and HER2/neu receptors. Carbonic anhydrase IX (CA IX) is a tumor-associated cell surface glycoprotein that is involved in adaptation to hypoxia-induced acidosis and plays a role in cancer progression. This study aimed to investigate CA IX expression in TNBC and its relationship with treatment effect.

NCT ID: NCT05750719 Completed - Clinical trials for Triple-Negative Breast Cancer

BRCA and NACT in TNBC Patients

Light-Bright
Start date: January 2, 2013
Phase:
Study type: Observational

The goal of this observational study is to evaluate data from patients with triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT) in order to better define the impact of germline BRCA1/2 (gBRCA1/2) mutation status on outcomes in this patient population. The aims of the study are: - To evaluate the rate of pathologic complete response (pCR) in patients with locally advanced TNBC who performed NACT, in relation to the mutational status of gBRCA. - To evaluate Evaluate Event Free survival (EFS) and Overall Survival (OS) in this patients population.

NCT ID: NCT05730010 Completed - Clinical trials for Triple Negative Breast Cancer

Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis

Start date: April 16, 2023
Phase:
Study type: Observational

This study will examine how ctDNA and additional prognostic genomic information in patients with early stage breast cancer might influences patient decision- making regarding systemic therapy options.

NCT ID: NCT05112536 Completed - Breast Cancer Clinical Trials

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

Start date: March 3, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the mechanism of action, as well as the safety and efficacy of trilaciclib in combination with standard of care treatment in the neoadjuvant setting of early-stage triple negative breast cancer (TNBC). This study will have four phases: 1) Screening Phase, 2) Trilaciclib Lead-In Phase, 3) Treatment Phase, and 4) Surgery and Follow-Up Phase. After a screening phase of up to 21 day, each participant will receive trilaciclib single-dose monotherapy during the lead-in phase, followed by a tumor biopsy. During the treatment phase, each participant will receive trilaciclib with standard of care chemotherapy. Immunotherapy may be included during the treatment phase, per standard of care. 3-5 weeks following conclusion of the treatment phase, each participant will undergo definitive surgery. A 30-day Safety Follow-up Visit will occur 30 days after the last dose of trilaciclib and an End of Study Visit will occur within 14 days after definitive surgery.

NCT ID: NCT05001347 Completed - Ovarian Cancer Clinical Trials

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

Start date: November 2, 2021
Phase: Phase 2
Study type: Interventional

This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors.

NCT ID: NCT04742959 Completed - Prostate Cancer Clinical Trials

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Start date: March 14, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.

NCT ID: NCT04664972 Completed - Clinical trials for Triple Negative Breast Cancer

Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC

Start date: November 23, 2018
Phase: Phase 2
Study type: Interventional

Previous studies have shown that TNBC is sensitive to DNA crosslinking-related chemotherapeutic drugs such as platinum. However, there is a lack of large sample prospective clinical data to compare the efficacy of TP and EC-T / TEC regimen in the neoadjuvant chemotherapy of TNBC. Besides, the application of anthracycline drugs is limited to a certain extent due to the cardiotoxicity. Based on the above evidence, the researchers hope to explore a more effective and safer new adjuvant therapy for TNBC.

NCT ID: NCT04613674 Completed - Clinical trials for Triple Negative Breast Cancer

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Start date: December 9, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of camrelizumab (an engineered anti-programmed death-ligand 1 [PD-1] antibody) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy in participants with triple negative breast cancer (TNBC). Participants will be randomized in a 1:1 ratio to Arm A (camrelizumab +chemotherapy) or Arm B (placebo + chemotherapy).

NCT ID: NCT04584112 Completed - Clinical trials for Triple-Negative Breast Cancer

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Start date: September 28, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of tiragolumab in combination with atezolizumab and chemotherapy in participants with metastatic and early triple-negative breast cancer (TNBC).

NCT ID: NCT04580485 Completed - Colorectal Cancer Clinical Trials

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Start date: February 3, 2021
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as monotherapy or in combination with INCMGA00012 in participants with selected CD8 T-cell-positive advanced solid tumors including SCCHN, NSCLC, ovarian cancer, CRPC, TNBC, bladder cancer, and specified GI malignancies (defined as CRC, gastric/GEJ cancer, HCC, PDAC, or SCAC)